Repository logo
 
Publication

Humoral immune response of SARS-CoV-2-infected patients with cancer: influencing factors and mechanisms

2021-05-20Journal article Restricted access
Simple item page
dc.contributor.authorEsperança Martins, Miguel
dc.contributor.authorGonçalves, Lisa
dc.contributor.authorSoares De Pinho, Inês
dc.contributor.authorGomes, Andreia
dc.contributor.authorMontesinos Serrano, Marta
dc.contributor.authorBlankenhaus, Birte
dc.contributor.authorFigueiredo-Campos, Patricia
dc.contributor.authorMarques, Ana Catarina
dc.contributor.authorCastro-Barbosa, Ana
dc.contributor.authorCardoso, Ana
dc.contributor.authorAntunes Meireles, Pedro
dc.contributor.authorAtalaia Barbacena, Henrique
dc.contributor.authorGaspar, Pedro
dc.contributor.authorHowell-Monteiro, Patrícia
dc.contributor.authorPais-de-Lacerda, António
dc.contributor.authorMota, Catarina
dc.contributor.authorVeldhoen, Marc
dc.date.accessioned2021-07-22T12:52:01Z
dc.date.available2021-07-22T12:52:01Z
dc.date.issued2021-05-20
dc.description© 2021 AlphaMed Press.pt_PT
dc.description.abstractBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients with cancer show worse outcomes compared with patients without cancer. The humoral immune response (HIR) of patients with cancer against SARS-CoV-2 is not well characterized. To better understand it, we conducted a serological study of hospitalized patients with cancer infected with SARS-CoV-2. Materials and methods: This was a unicentric, retrospective study enrolling adult patients with SARS-CoV-2 admitted to a central hospital from March 15 to June 17, 2020, whose serum samples were quantified for anti-SARS-CoV-2 receptor-binding domain or spike protein IgM, IgG, and IgA antibodies. The aims of the study were to assess the HIR to SARS-CoV-2; correlate it with different cancer types, stages, and treatments; clarify the interplay between the HIR and clinical outcomes of patients with cancer; and compare the HIR of SARS-CoV-2-infected patients with and without cancer. Results: We included 72 SARS-CoV-2-positive subjects (19 with cancer, 53 controls). About 90% of controls revealed a robust serological response. Among patients with cancer, a strong response was verified in 57.9%, with 42.1% showing a persistently weak response. Treatment with chemotherapy within 14 days before positivity was the only factor statistically shown to be associated with persistently weak serological responses among patients with cancer. No significant differences in outcomes were observed between patients with strong and weak responses. All IgG, IgM, IgA, and total Ig antibody titers were significantly lower in patients with cancer compared with those without. Conclusion: A significant portion of patients with cancer develop a proper HIR. Recent chemotherapy treatment may be associated with weak serological responses among patients with cancer. Patients with cancer have a weaker SARS-CoV-2 antibody response compared with those without cancer. Implications for practice: These results place the spotlight on patients with cancer, particularly those actively treated with chemotherapy. These patients may potentially be more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, so it is important to provide oncologists further theoretical support (with concrete examples and respective mechanistic correlations) for the decision of starting, maintaining, or stopping antineoplastic treatments (particularly chemotherapy) not only on noninfected but also on infected patients with cancer in accordance with cancer type, stage and prognosis, treatment agents, treatment setting, and SARS-CoV-2 infection risks.pt_PT
dc.description.sponsorshipLtoINNOV), the Fundação para a Ciência e a Tecnologia (SFRH/BD/131605/2017), and research4COVID19 (231_596873172, generating SARS-CoV-2 seroconversion assay), with additional support by Sociedade Francisco Manuel dos Santos.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationThe Oncologist 2021;26:1–14pt_PT
dc.identifier.doi10.1002/onco.13828pt_PT
dc.identifier.eissn1549-490X
dc.identifier.issn1083-7159
dc.identifier.urihttp://hdl.handle.net/10451/49053
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherJohn Wiley & Sons, Inc.pt_PT
dc.relation“How to activate non-conventional Epithelial T cells”
dc.relation.publisherversionhttps://theoncologist.onlinelibrary.wiley.com/journal/1549490xpt_PT
dc.subjectAntibody responsept_PT
dc.subjectCancerpt_PT
dc.subjectImmunoglobulinpt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectSerologicalpt_PT
dc.titleHumoral immune response of SARS-CoV-2-infected patients with cancer: influencing factors and mechanismspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitle“How to activate non-conventional Epithelial T cells”
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/OE/SFRH%2FBD%2F131605%2F2017/PT
oaire.citation.titleThe Oncologistpt_PT
oaire.fundingStreamOE
person.familyNameEsperança Martins
person.familyNameSoares de Pinho
person.familyNamedos Santos Gomes
person.familyNameMontesinos Serrano
person.familyNameBlankenhaus
person.familyNameFigueiredo-Campos
person.familyNameMarques
person.familyNameAntunes Meireles
person.familyNameAtalaia Barbacena
person.familyNameGaspar
person.familyNameMota da Silva
person.familyNameVeldhoen
person.givenNameMiguel
person.givenNameInês
person.givenNameAndreia Filipa
person.givenNameMarta
person.givenNameBirte
person.givenNamePatricia
person.givenNameAna Catarina
person.givenNamePedro
person.givenNameHenrique
person.givenNamePedro
person.givenNameMaria Catarina
person.givenNameMarc
person.identifier1201606
person.identifierhttps://scholar.google.pt/citations?hl=en&user=7vG1jLIAAAAJ
person.identifier.ciencia-id1D1E-DE66-DB38
person.identifier.ciencia-idFD19-D7A4-E29D
person.identifier.ciencia-idEC16-8D36-C5F9
person.identifier.ciencia-id4610-8D0C-BE0B
person.identifier.ciencia-id351B-8D25-ECDF
person.identifier.ciencia-idCC13-C7B0-19F5
person.identifier.ciencia-id6413-A3A0-C7AD
person.identifier.orcid0000-0002-6858-7341
person.identifier.orcid0000-0002-8377-0179
person.identifier.orcid0000-0003-2605-2565
person.identifier.orcid0000-0002-1897-3981
person.identifier.orcid0000-0003-0987-5228
person.identifier.orcid0000-0002-9808-6230
person.identifier.orcid0000-0003-3152-1792
person.identifier.orcid0000-0002-3356-1969
person.identifier.orcid0000-0002-2270-8275
person.identifier.orcid0000-0002-6965-3435
person.identifier.orcid0000-0002-1478-9562
person.identifier.scopus-author-id8323789000
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicatione73cbe66-c79a-4f6b-9bed-b3af464000db
relation.isAuthorOfPublication175aa033-b64e-4a94-b8c8-8bed65034181
relation.isAuthorOfPublicationed116f9d-03a0-4fcc-ab15-5aa484143268
relation.isAuthorOfPublication81dfbbc5-6cf9-4bf2-8f0f-f818850470c0
relation.isAuthorOfPublication2d28ba54-99dc-4339-8105-58809bce40c2
relation.isAuthorOfPublication0aa06c83-fd50-4c84-a33b-c930e6ac7871
relation.isAuthorOfPublicationc7cb1622-522b-4c0f-804f-e32b0dddaa37
relation.isAuthorOfPublication8f9dcba9-80fe-4204-972b-eb160510f83a
relation.isAuthorOfPublicationf6204cec-779a-4e33-8d3a-b804ffcf238f
relation.isAuthorOfPublication4a8e5a14-5788-4327-a4c5-662c358507c2
relation.isAuthorOfPublication293e52d4-2c20-4307-aa27-680d2400bb6b
relation.isAuthorOfPublicationb6ddef66-b6bb-4ce5-b68a-e4b211aa2411
relation.isAuthorOfPublication.latestForDiscoverye73cbe66-c79a-4f6b-9bed-b3af464000db
relation.isProjectOfPublicationd5c3fafe-f274-451b-9754-d3d1d6dcd53b
relation.isProjectOfPublication.latestForDiscoveryd5c3fafe-f274-451b-9754-d3d1d6dcd53b

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Humoral_immune.pdf
Size:
1.71 MB
Format:
Adobe Portable Document Format
Download

Collections

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais